ストックスクリーナーアプリを入手
54.24
1.36%
-0.75
前日終値:
$54.99
開ける：
$54.09
24時間の取引高:
604.91K
Relative Volume:
0.89
時価総額：
$3.33B
収益：
$900.66M
当期純損益:
$-453.20M
株価収益率:
-9.1313
EPS:
-5.94
ネットキャッシュフロー:
$-274.19M
1週間 パフォーマンス:
-5.08%
1か月 パフォーマンス:
+7.26%
6か月 パフォーマンス:
+44.41%
1年 パフォーマンス:
+86.46%
1日の値動き範囲:
$53.53
$55.28
1週間の範囲:
$53.53
$57.97
52週間の値動き範囲:
$24.00
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
名前
Ptc Therapeutics Inc
セクター
電話
(908) 222-7000
住所
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
PTCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
54.24 | 3.33B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-11 | アップグレード | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 開始されました | Scotiabank | Sector Perform |
| 2024-12-13 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-09-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-08-26 | 再開されました | UBS | Buy |
| 2024-05-20 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-10-30 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-10-27 | ダウングレード | Citigroup | Neutral → Sell |
| 2023-10-06 | ダウングレード | Truist | Buy → Hold |
| 2023-09-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-09-15 | ダウングレード | Raymond James | Outperform → Underperform |
| 2023-03-17 | 開始されました | SVB Securities | Market Perform |
| 2022-12-14 | 開始されました | Goldman | Sell |
| 2022-09-12 | 開始されました | Jefferies | Buy |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-10-18 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-29 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-01-05 | アップグレード | Citigroup | Neutral → Buy |
| 2020-11-30 | ダウングレード | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-10-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-04-09 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-02-20 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-05-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 開始されました | Bernstein | Outperform |
| 2018-10-03 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 開始されました | Credit Suisse | Outperform |
| 2018-06-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2017-10-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | ダウングレード | JP Morgan | Neutral → Underweight |
すべてを表示
Ptc Therapeutics Inc (PTCT) 最新ニュース
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StreetInsider.com
PTC Therapeutics Faces EU Setback on Translarna - TipRanks
PTC Therapeutics says EC will not renew market authorization for muscle disorder drug - Marketscreener.com
PTC Therapeutics stock slips as EU ends Translarna nod (PTCT) - Seeking Alpha
PTC Therapeutics faces EC setback on Translarna in Europe - Investing.com
PTC Therapeutics (PTCT) Faces EU Setback for DMD Drug Translarna - GuruFocus.com
European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder - Benzinga
PTC Therapeutics says EC not to renew market authorization for muscle disorder drug - Marketscreener.com
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe - Quantisnow
PTC Therapeutics Loses EU Authorization for Translarna in Duchenne Muscular Dystrophy - Marketscreener.com
PTC Therapeutics: European Commission Decides To Adopt CHMP Negative Opinion On Translarna - Nasdaq
PTC Therapeutics says European Commission will remove muscle disorder drug - Marketscreener.com
PTC Therapeutics Provides Regulatory Update On Translarna(TM) (Ataluren) In Europe - Marketscreener.com
PTC Therapeutics faces EC setback on Translarna in Europe By Investing.com - Investing.com Australia
Natixis Advisors LLC Makes New $544,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Sector Gamma AS Purchases Shares of 65,250 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
A Shareholder alert for PTC Therapeutics, Inc was sent by Bronstein, Gewirtz and Grossman, LLC to Lead Class Action Lawsuit! - ACCESS Newswire
Cibc World Markets Corp Invests $322,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
AlphaQuest LLC Has $49,000 Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Sets New 52-Week HighShould You Buy? - MarketBeat
First Week of May 16th Options Trading For PTC Therapeutics - Nasdaq
Leigh Syndrome Treatment Market Size in 7MM is expected to grow - openPR
Connor Clark & Lunn Investment Management Ltd. Sells 15,278 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Proficio Capital Partners LLC Takes $758,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Stephanie Okey Sells 5,000 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
Insider Sell Alert: Eric Pauwels Sells Shares of PTC Therapeutics Inc (PTCT) - GuruFocus.com
Charles Schwab Investment Management Inc. Trims Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics reports progress in PKU treatment study By Investing.com - Investing.com Australia
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July - Benzinga
PTC Therapeutics reports progress in PKU treatment study - Investing.com India
PTCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PTC Therapeutics, Inc Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JPMorgan Chase & Co. Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $78.00 - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month High After Analyst Upgrade - MarketBeat
PTC Therapeutics chief business officer sells $630,104 in stock - Investing.com India
PTC Therapeutics chief business officer sells $630,104 in stock By Investing.com - Investing.com UK
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Mark Elliott Boulding Sells 15,521 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
Director Okey Stephanie sold $270,000 worth of shares (5,000 units at $54.00), decreasing direct ownership by 36% to 8,867 units (SEC Form 4) - Quantisnow
PTCT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PTC Therapeutics, Inc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
PTC Therapeutics upgraded at BofA on FDA review for Friedreich's ataxia drug - MSN
PTC Therapeutics (NASDAQ:PTCT) Rating Increased to Neutral at Bank of America - MarketBeat
GC Wealth Management RIA LLC Purchases Shares of 8,032 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics exec. VP Boulding sells $827,232 in stock By Investing.com - Investing.com Australia
PTC Therapeutics exec. VP Boulding sells $827,232 in stock - Investing.com
Ptc Therapeutics Inc (PTCT) 財務データ
収益
当期純利益
現金流量
EPS
Ptc Therapeutics Inc (PTCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pauwels Eric | CHIEF BUSINESS OFFICER |
Mar 14 '25 |
Sale |
55.19 |
4,458 |
246,037 |
79,402 |
| Okey Stephanie | Director |
Mar 13 '25 |
Sale |
54.00 |
5,000 |
270,000 |
8,867 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):